Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions

 Revenio Group Corporation, Stock Exchange Release, November 4, 2016 at 9.15

 Managers' transactions

 Person subject to the notification requirement

 Name:                          Salovaara Olli-Pekka Legal Person

 Position:                      Chief Executive Officer


----------------------------------------------------------------------------
 Initial Notification


----------------------------------------------------------------------------
 Issuer

 Name:                          Revenio Group Oyj


----------------------------------------------------------------------------
 Transaction details

 Transaction date:              31-10-2016

 Nature of the transaction:     Gift, Donation or Inheritance (Received)



 Instrument:                    Share

 ISIN:                          FI0009010912



 Volume:                        840

 Unit price:                    25,50000 Euro



 Aggregated transactions

 Volume:                        840

 Volume weighted average price: 25.50000 Euro

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

DISTRIBUTION:

Nasdaq Helsinki

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.


[]